Prothena Corp (PRTA) 44.01 $PRTA Prothena to Participate

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Prothena Corp (PRTA) 44.01 $PRTA

Prothena to Participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Wed Jul 06, 3:05PM CDT
Prothena Corporation plc (NASDAQRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 12 at 11:45 AM ET in New York, NY.
PRTA: 44.01 (+2.28)

Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis
Globe Newswire - Tue Jul 05, 6:00AM CDT
- New data from Phase 1/2 dose-escalation (n=27) and expansion (n=42) study show best response rates in total cardiac- and renal- evaluable patients of 53% and 63%, respectively, that are consistent with those previously published in the Journal of Clinical Oncology
PRTA: 44.01 (+2.28)

Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases
Globe Newswire - Thu Jun 09, 3:05PM CDT
- All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteers
PRTA: 44.01 (+2.28)

Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
Globe Newswire - Mon May 23, 3:05PM CDT
- New clinical data to be presented from expansion cohort of Phase 1/2 trial of NEOD001 for the potential treatment of AL amyloidosis
PRTA: 44.01 (+2.28)

Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress
Globe Newswire - Thu May 19, 3:05PM CDT
DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NasdaqRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that data from multiple quality of life studies in patients with AL amyloidosis will be highlighted at The European Hematology Association (EHA) 21st Congress to be held June 9-12 in Copenhagen, Denmark.
PRTA: 44.01 (+2.28)

Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016
Globe Newswire - Mon May 09, 3:05PM CDT
DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NasdaqRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its Phase 1 single ascending dose study of PRX003 in healthy volunteers will be highlighted in an oral presentation at The European League Against Rheumatism Annual European Congress of Rheumatology (EULAR 2016) to be held June 8-11 in London.
PRTA: 44.01 (+2.28)

Prothena (PRTA) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed May 04, 12:00PM CDT
Prothena Corporation plc (PRTA) reported a loss of 81 cents per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 70 cents.
SHPG: 188.21 (-1.31), PRTA: 44.01 (+2.28), NKTR: 14.92 (+0.62)

Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update
Globe Newswire - Tue May 03, 3:05PM CDT
- Net cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million, including net proceeds of $128.6 million raised through January 2016 public equity offering, supports advancement of multiple clinical development programs
PRTA: 44.01 (+2.28)

Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:04AM CDT
The going has been quite satisfactory as we stand in the thick of the first earnings season of the year.
MACK: 5.62 (unch), BIIB: 251.30 (+4.03), ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), AERI: 17.61 (+0.07), AEGR: 1.67 (+0.02), PRTA: 44.01 (+2.28)

Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 48.50 (+0.81), AGIO: 42.75 (+0.12), PRTA: 44.01 (+2.28)

Data from Prothena's Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid
Globe Newswire - Wed Mar 16, 3:05PM CDT
Antibodies bind specifically to misfolded, non-native forms of transthyretin, disrupting fibril formation
PRTA: 44.01 (+2.28)

Data From Prothena's Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology
Globe Newswire - Tue Feb 09, 7:10AM CST
Interim Results Previously Presented at Meetings of the American Society for Clinical Oncology and the European Hematology Association
PRTA: 44.01 (+2.28)

Prothena to Report Fourth Quarter and Full Year 2015 Financial Results and Host Webcast Conference Call on February 18
GlobeNewswire - Thu Feb 04, 3:06PM CST
Prothena Corporation plc (NasdaqRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year 2015 financial results on Thursday, February 18, 2016, after the close of the U.S. financial markets. The announcement will be followed by a live audio webcast and conference call at 4:30 PM ET.
PRTA: 44.01 (+2.28)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Csquare Investors Face Tough Questions Amid Probe

Updated Category News Views 72

Csquare's Shaky Claims and Market Consequences When a company flashes big numbers like $356 million to showcase its financial health, it sure gets the ticker NYSE:CSQR buzzing. But here's the rub—over half of that is locked up tighter than a drum, off-limits for general use. You gotta appreciate the irony, right? Someone's turned up a rock and there it is, a mess of...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 231

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 200

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Hims & Hers Faces Securities Lawsuit Amid Stock Dive

Updated Category News Views 139

Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 104

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading
Beta Bionics Faces Class Action Lawsuit Amid FDA Concerns

Updated Category News Views 252

Beta Bionics in the Legal Crosshairs When a company like Beta Bionics gets hauled into court, you know it's not just smoky mirrors and boardroom politics. The stakes are high right now, with investors lining up for a class-action lawsuit that zeroes in on a nasty bundle of allegations. This isn't just a blip on the radar. It's a seismic wave in the industry. Allegations...

Continue Reading
Denarius Metals Unveils Technical Insight for Toral Project

Updated Category News Views 44

Denarius Metals Shares Tech Report on Toral Project It's a curious moment in the mining world when Denarius Metals decides to drop their latest gem—a technical report on the Toral Project. We're talking about a full-bodied document rooted in the stringent National Instrument 43-101 standards. This isn't some half-baked release; it's a robust assertion of where they...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 98

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 79

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 74

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading

Top 5 Most Recently Viewed Articles

KuCoin Introduces Global Sell-to-Card for 41 Fiat Currencies

Updated Category News Views 169

KuCoin Unveils Improved Sell-to-Card Feature for Users KuCoin, a trusted name in the cryptocurrency arena, has announced an exciting enhancement to its Fast Trade platform. This upgrade includes the introduction of a global Sell-to-Card feature, which allows users to convert USDT into 41 different fiat currencies and seamlessly withdraw these funds to their Visa or...

Continue Reading
Helen Of Troy Surprises with Positive Earnings Amid Market Moves

Updated Category News Views 88

U.S. Markets Show Mixed Signals as Dow Surges The trading day started off with mixed results as the U.S. stock market revealed contrasting trends among its key indices. The Dow Jones Industrial Average notably climbed over 100 points, indicating strength in some segments of the market. Market Movements As the market opened, the Dow experienced an increase of 0.35%,...

Continue Reading
Exploring the Growth of $1000 Investment in Cencora Stock

Updated Category News Views 87

The Growth Journey of Cencora Investments Cencora (NYSE: COR) has showcased remarkable performance over the past five years, demonstrating its ability to grow even amidst market ups and downs. Its position in the market has been bolstered by an outstanding annual return rate of 23.07%, surpassing many of its competitors. With a current market capitalization of around...

Continue Reading
WORK Medical Innovates Through Strategic RWA Partnerships

Updated Category News Views 182

WORK Medical Ventures into RWA Tokenization WORK Medical Technology Group Ltd. is embarking on an exciting journey to integrate real-world asset (RWA) technology into its operations. This innovative approach aims to transform the company's existing product systems and embrace advancements in artificial intelligence (AI). Strategic Partnerships In its latest move, WORK...

Continue Reading
Carrier Global Corporation Announces Conference Participation

Updated Category News Views 189

Carrier Global Corporation at the Annual Morgan Stanley Laguna Conference Carrier Global Corporation (NYSE: CARR), a prominent name in intelligent climate and energy solutions, is set to make waves at the 13th Annual Morgan Stanley Laguna Conference. The event, taking place in a friendly atmosphere, will feature Carrier's Chairman and CEO, David Gitlin, along with Senior...

Continue Reading